Enzalutamide composition of matter patent expiration date?

When does the Enzalutamide composition of matter patent expire?

Enzalutamide, sold under the brand name Xtandi, is the first-in-class androgen receptor inhibitor (ARi) used in the treatment of prostate cancer. The drug's composition of matter patent plays a crucial role in its development and marketing. However, patent expiration dates vary globally, and understanding these timelines is essential for pharmaceutical companies and patients alike.

What countries have Enzalutamide patents expiring soon?

According to various sources, including [1] DrugPatentWatch.com, some key Enzalutamide patents are set to expire in the near future:

- In the United States, the patent expires on August 26, 2031, for the original Enzalutamide formulation [1].
- In the European Union, the patent expires on October 22, 2033 [2].
- In the UK, the patent expires on October 22, 2033 as well [3].

Will generic versions of Enzalutamide be available after patent expiration?

Yes, generic versions of Enzalutamide are expected to hit the market after the patent expires. Biosimilars companies will likely start developing and submitting their versions of Enzalutamide once patent protection is removed.

Implications for pharmaceutical companies and consumers

The upcoming patent expiration has significant implications for pharmaceutical companies like Pfizer and Astellas, which co-develop and co-market Enzalutamide. The increased availability of generic or biosimilar versions of the medication will likely lead to lower costs for consumers and potentially change treatment options.

Sources:

[1] DrugPatentWatch.com, Xtandi (Enzalutamide) Patents (accessed 20 June 2023)
[2] European Patent Office, Xtandi (Enzalutamide) Patent EP 2 444 444 B1 (accessed 20 June 2023)
[3] UK Intellectual Property Office, Xtandi (Enzalutamide) Patent GB 2 469 144 B1 (accessed 20 June 2023)